Anti-Tumor Efficiency of Perillylalcohol/beta-Cyclodextrin Inclusion Complexes in a Sarcoma S180-Induced Mice Model
authors Rezende, AA; Santos, RS; Andrade, LN; Amaral, RG; Pereira, MM; Bani, C; Chen, M; Priefer, R; da Silva, CF; de Albuquerque, RLC; Souto, EB; Severino, P
nationality International
journal PHARMACEUTICS
author keywords perillyl alcohol; cyclodextrin; inclusion complex; anti-cancer; sarcoma
keywords BETA-CYCLODEXTRIN; PERILLYL ALCOHOL; ESSENTIAL OIL; MONOTERPENE PRESENT; ANIMAL-MODEL; DOCKING; CANCER; ENCAPSULATION; OPTIMIZATION; CARVACROL
abstract The low solubility and high volatility of perillyl alcohol (POH) compromise its bioavailability and potential use as chemotherapeutic drug. In this work, we have evaluated the anticancer activity of POH complexed with beta-cyclodextrin (beta-CD) using three complexation approaches. Molecular docking suggests the hydrogen-bond between POH and beta-cyclodextrin in molar proportion was 1:1. Thermal analysis and Fourier-transform infrared spectroscopy (FTIR) confirmed that the POH was enclosed in the beta-CD cavity. Also, there was a significant reduction of particle size thereof, indicating a modification of the beta-cyclodextrin crystals. The complexes were tested against human L929 fibroblasts after 24 h of incubation showing no signs of cytotoxicity. Concerning the histopathological results, the treatment with POH/beta-CD at a dose of 50 mg/kg promoted approximately 60% inhibition of tumor growth in a sarcoma S180-induced mice model and the reduction of nuclear immunoexpression of the Ki67 antigen compared to the control group. Obtained data suggest a significant reduction of cycling cells and tumor proliferation. Our results confirm that complexation of POH/beta-CD not only solves the problem related to the volatility of the monoterpene but also increases its efficiency as an antitumor agent.
publisher MDPI
isbn 1999-4923
year published 2021
volume 13
issue 2
digital object identifier (doi) 10.3390/pharmaceutics13020245
web of science category 18
subject category Pharmacology & Pharmacy
unique article identifier WOS:000623009500001
  ciceco authors
  impact metrics
journal analysis (jcr 2019):
journal impact factor 4.421
5 year journal impact factor Not Available
category normalized journal impact factor percentile 83.889
dimensions (citation analysis):
altmetrics (social interaction):



 


Apoio

1suponsers_list_ciceco.jpg